Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

The Impact of Multimodal Brain Monitoring on Postoperative Outcomes in Elderly Patients Undergoing Major Abdominal Surgery

keskiviikko 15. heinäkuuta 2026 päivittänyt: Xuanwu Hospital, Beijing

Impact of Multimodal Brain Monitoring Under General Anesthesia on Postoperative Outcomes in Elderly Patients Undergoing Major Abdominal Surgery: A Multicenter, Prospective, Single-blind, Randomized Controlled Study

The purpose of this clinical trial is to investigate the effect of multimodal brain monitoring under general anesthesia on postoperative outcomes in elderly patients undergoing abdominal surgery.The research hypothesis is that multimodal brain monitoring under general anesthesia can reduce the incidence of postoperative composite complications and improve postoperative outcomes in elderly patients undergoing major abdominal surgery.

Eligible patients will be randomly assigned in a 1:1 ratio to the Multimodal Brain Monitoring under General Anesthesia Group (MBMGA group) and the Bispectral Index Monitoring under General Anesthesia Group (BIS group). The primary outcome is the postoperative composite complication rate . Secondary outcomes include intraoperative hyperglycemia, adverse events during anesthesia induction and maintanance, changes in blood pressure and heart rate, intraoperative hypotension, the dosage of perioperative anesthetics and vasoactive drugs, changes in serum cortisol, cardiac troponin I, blood creatinine (Cr) level, extubation time and awake time, the rate of transferring to ICU or AICU, The time to first use analgesia pump and the cumulative dose of postoperative oxycodone, systemic complications, hospitalization time, first exhaust time , first oral intake time, rate of second surgery and mortality within 30 days postoperatively.

Participants will:

  1. Undergo routine preoperative fasting for 6-8 hours;
  2. Prior to anesthesia induction, cooperate with the establishment of intravenous access, arterial catheterization, monitoring of physiological parameters, blood sample collection, and receive fluid preloading;
  3. During surgery, for patients in the MBMGA group , propofol and remifentanyl will be adjusted according to multimodal brain monitoring indices (WLi and PTi), while for patients in the BIS group, only propofol will be adjusted based on bispectral index and remifentanyl will be adjusted according to anesthesiologists' experience; simultaneously, vital signs, including respiration, body temperature, fluid therapy, blood pressure, and heart rate regulation, will be monitored and managed.
  4. After surgery, endotracheal tubes will be removed once extubation criteria are met, and patients will be transferred to the PACU, where they will receive routine monitoring and will be discharged from the PACU upon meeting corresponding scoring criteria;
  5. Participates in follow-ups on the day of surgery and for 1-30 days postoperatively, during which investigators will record the primary outcome and secondary outcomes.

Tutkimuksen yleiskatsaus

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

368

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Tutki yhteystietojen varmuuskopiointi

  • Nimi: Wei Xiao, Doctor
  • Puhelinnumero: 008613810971299
  • Sähköposti: kitten15@126.com

Opiskelupaikat

    • Beijing Municipality
      • Beijing, Beijing Municipality, Kiina
        • Peking University International Hospital
        • Ottaa yhteyttä:
        • Päätutkija:
          • Lan Yao
      • Beijing, Beijing Municipality, Kiina, 10053
        • Xuanwu Hospital Capital Medical University
        • Ottaa yhteyttä:
          • Wei Xiao, Doctor
          • Puhelinnumero: 008613810971299
          • Sähköposti: kitten15@126.com
        • Päätutkija:
          • Tianlong Wang
        • Alatutkija:
          • Wei Xiao
    • Henan
      • Zhengzhou, Henan, Kiina
        • The First Affiliated Hospital of Zhengzhou University
        • Päätutkija:
          • Jianjun Yang
        • Ottaa yhteyttä:
    • Hubei
      • Wuhan, Hubei, Kiina
        • Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology
        • Ottaa yhteyttä:
        • Päätutkija:
          • Ailin Luo

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

  • Vanhempi Aikuinen

Hyväksyy terveitä vapaaehtoisia

Ei

Kuvaus

Inclusion Criteria:

Aged ≥65 years, regardless of gender; Scheduled for elective abdominal surgery with general anesthesia duration (from anesthesia induction to surgery completion) ≥ 2 hours; American Society of Anesthesiologists (ASA) physical status classification of I-III; Body mass index (BMI) of 18.5-29.9 kg/m²; Postoperative hospital stay expected to exceed 72 hours; Compliant with ethical standards, with voluntary signed informed consent.

Exclusion Criteria:

Severe cardiovascular diseases, including:

History of myocardial infarction within the past 6 months; Bradycardia (resting heart rate <50 beats/min); Uncontrolled hypertension (sitting systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg during screening); Sitting systolic blood pressure ≤90 mmHg during screening; History of severe valvular heart disease; Uncontrolled severe respiratory infections: e.g., severe pneumonia, acute bronchitis.

Abnormal liver function: Aspartate Aminotransferase (AST) and/or Alanine Aminotransferase (ALT) ≥2.5×Upper Limit of Normal (ULN), Total Bilirubin (TBIL) ≥1.5×Upper Limit of Normal (ULN); Abnormal renal function: urea or blood urea nitrogen (BUN) ≥1.5×Upper Limit of Normal (ULN), serum creatinine >Upper Limit of Normal (ULN); Admission hemoglobin A1c (HbA1c) ≥6.5% or ≥2 fasting blood glucose measurements ≥180 mg/dl (10 mmol/L) and/or random blood glucose ≥200 mg/dL (≈11.1 mmol/L); Preoperative anemia (Hemoglobin [Hb] ≤90 g/L), thrombocytopenia (Platelet [PLT] ≤80×10⁹/L), hypoproteinemia (Albumin [Alb] ≤30 g/L); History of drug abuse and/or alcoholism within the past 2 years (alcoholism defined as daily average alcohol consumption >2 units, where 1 unit = 360 mL beer or 45 mL 40% ethanol liquor or 150 mL wine); Neurological diseases (e.g., stroke within 6 months, Alzheimer's disease, Parkinson's disease, mental disease, myasthenia gravis) or psychiatric disorders (e.g., schizophrenia, mania, bipolar disorder, delirium), history of long-term use of neuropsychiatric medications, or cognitive impairment; Allergy or contraindication to study medications; Patients refusing or unable to cooperate with the study; Scheduled for pancreatic surgery; Other conditions deemed inappropriate for participation by the investigator.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Ennaltaehkäisy
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Kaksinkertainen

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Multimodal Brain Monitoring Guided Anesthesia Group(MBMGA Group)
The dosage of propofol is adjusted to maintain WLi in the range of 40-70. While the dosage of remifentanil is adjusted to maintain PTi in the range of 40-70. When intraoperative pain stimulation suddenly increases ( PTi > 70 ) and lead to increased heart rate and elevated blood pressure, remifentanil 0.5-1 μg / kg will be intravenously injected and observed for 1 min. If PTi still is > 70, remifentanil 0.5-1 μg / kg will be added again until PTi reached 40-70.
During the anesthesia induction phase, the dosage administration is guided by the goal of reducing PTi to the range of 40-70, and tracheal intubation is performed when both PTi and WLI are within 40-70. In the anesthesia maintenance phase, the propofol dosage is adjusted according to the WLI value to maintain WLI within 40-70, while the remifentanil dosage is adjusted based on the PTi value to keep PTi within 40-70. In the event of sudden increased intraoperative pain stimulation (PTi > 70) accompanied by tachycardia and hypertension, an intravenous bolus of remifentanil at 0.5-1 μg/kg is administered; after 1 minute of observation, if PTi remains > 70, an additional 0.5-1 μg/kg of remifentanil is given until PTi is brought back to the 40-70 range.
Active Comparator: Bispectral Index (BIS) Monitoring Guided Anesthesia Group( BIS Group)
The dosage of propofol is adjusted according to the value of BIS, and the BIS is maintained in the range of 40 ~ 60. The dosage of remifentanil is adjusted according to the experience of anesthesiologists. The intraoperative remifentanil dosage will be maintained between 0.1 μg/kg/min and 0.3μg/kg/min.When it is highly suspected that the sudden increase of pain stimulation during operation leads to the increase of heart rate and blood pressure, remifentanil 0.5 ~ 1 μg / kg will be given intravenously for 1 min. If the heart rate and blood pressure level don't improve, remifentanil 0.5 ~ 1 μg / kg is added again until the heart rate and blood pressure have a downward trend and return to the level before the increase.
During the anesthesia induction phase, the dosage administration is guided by the goal of reducing BIS to the range of 40-60, with remifentanil supplemented based on clinical experience. In the anesthesia maintenance phase, the propofol dosage is adjusted according to BIS values to maintain BIS within 40-60, while the remifentanil dosage is adjusted based on anesthesiologists' experience. When there is a high suspicion of sudden tachycardia and hypertension induced by increased intraoperative pain stimulation, an intravenous bolus of remifentanil at 0.5-1 μg/kg is administered; after 1 minute of observation, if heart rate and blood pressure show no improvement, an additional 0.5-1 μg/kg of remifentanil is given until there is a downward trend in heart rate and blood pressure and they return to pre-stimulation levels.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Incidence of Postoperative Composite Complication
Aikaikkuna: From post-extubation to postoperative Day 30
The incidence of ≥ 1 complication occurred from the extubation to the 30 th day postoperatively The definition of postoperative composite complications refers to the rate of occurrence of one or more complications from the time of anesthesia extubation to postoperative day 7 (or the day of discharge) and within 30 days after surgery. Postoperative complications are defined as adverse events of Clavien Dindo grade II or higher occurring in any system from postoperative day 1 to day 7 (or the day of discharge) and within 30 days after surgery.
From post-extubation to postoperative Day 30

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Incidence of intraoperative stress-induced hyperglycemia
Aikaikkuna: From anesthesia induction to skin closure, assessed up to 5 minutes after surgery

Intraoperative stress hyperglycemia is defined as:

A condition diagnosed when a patient meeting all the following criteria:

Preoperative glycemic status:

Two or more fasting blood glucose measurements < 126 mg/dL (≈7.0 mmol/L) or Random blood glucose < 200 mg/dL (≈11.1 mmol/L) during hospitalization, With concurrent HbA1c < 6.5%;

Intraoperative finding:

Highest blood glucose level ≥ 140 mg/dL (≈7.8 mmol/L) when measured at:

1 hour after intubation and/or Upon completion of surgery.

From anesthesia induction to skin closure, assessed up to 5 minutes after surgery
Incidence of intraoperative composite adverse events
Aikaikkuna: during operation, assessed up to 5 minutes after surgery

Observe and record the incidence of intraoperative composite adverse events .

Adverse events include but are not limited to:

  1. Cardiovascular Complications:

    • Hypotension

      • Hypertension

        • Severe Arrhythmia ④Acute Myocardial Ischemia

          • Acute Myocardial Infarction ⑥Acute Pulmonary Embolism

            • Acute Heart Failure ⑧Deep Vein Thrombosis
  2. Respiratory Complications:

    • Pneumonia

      • Acute Respiratory Distress Syndrome (ARDS)

        • Pulmonary Edema ④Respiratory Failure ⑤Bronchospasm

          ⑥Atelectasis

          ⑦Pleural Effusion

  3. Neurological Complications:

    ①Intraoperative Awareness

    ②Acute Stroke

  4. Renal Complications:

    • Acute Kidney Injury (AKI) ②Acute Renal Failure (ARF)
during operation, assessed up to 5 minutes after surgery
Blood pressure change immediately after intubation
Aikaikkuna: at anesthesia induction and immediately after intubation, assessed up to 10 seconds after intubation
Record blood pressure before induction and immediately after completion of intubation, and calculate the magnitude of change.
at anesthesia induction and immediately after intubation, assessed up to 10 seconds after intubation
Duration of intraoperative hypotension
Aikaikkuna: From the anesthesia induction to the end of surgery, assesed up to 5 minutes after surgery

Parameters to be recorded:

Duration of intraoperative hypotension;

Hypotension is defined as:

Mean arterial pressure < 65 mmHg or decrease of mean arterial pressure > 20% from preoperative baseline value.

From the anesthesia induction to the end of surgery, assesed up to 5 minutes after surgery
Total pintraoperative anesthetic/vasoactive drug dosages
Aikaikkuna: from the anesthesia induction to the end of surgery, assessed up to 5 minutes after surgery

Record the dosages of all medications administered during the intraoperative period, including but not limited to:

General anesthetics: Propofol, Remifentanil, Sufentanil, Oxycodone

Vasoactive agents:

  • Norepinephrine
  • Esmolol
  • Urapidil
  • Atropine
  • Ephedrine
  • Phenylephrine
from the anesthesia induction to the end of surgery, assessed up to 5 minutes after surgery
Serum cortisol levels before surgery and 24 hours postoperatively
Aikaikkuna: From before surgery and 24 hours post-operation

Measure serum cortisol concentrations at the following time points:

Preoperatively and 24 hours postoperatively

From before surgery and 24 hours post-operation
Durations from drug cessation to awake/extubation
Aikaikkuna: From drug cessation to awake/extubation , assessed up to 2 hours after entering post-anesthsia care unit
Duration from anesthesia discontinuation to awake and duration from anesthesia discontinuation to extubation
From drug cessation to awake/extubation , assessed up to 2 hours after entering post-anesthsia care unit
Rate of postoperative Intensive Care Unit/Anesthesia Intensive Care Unit transfer
Aikaikkuna: From the end of surgery to Discharge, assessed up to 2 weeks after surgery
The ratio of postoperative patients requiring transfer to either the Anesthesia Intensive Care Unit or Intensive Care Unit for any clinical indication, to the total number of surgical patients during the same period.
From the end of surgery to Discharge, assessed up to 2 weeks after surgery
Duration to first patient controlled intravenous analgesia pump use
Aikaikkuna: From the initiation of patient controlled intravenous analgesia pump use to the discontinuation of analgesic pump use, assessed up to 3 days after surgery
The duration from the end of surgery until the first activation of the patient controlled intravenous analgesia pump
From the initiation of patient controlled intravenous analgesia pump use to the discontinuation of analgesic pump use, assessed up to 3 days after surgery
Incidence of complications in other organ systems during the follow-up period except stress induced hyperglycemia
Aikaikkuna: From the start of surgery to 30 days post-operation

Follow-up assessments will be performed by a single blinded and certified anesthesia practitioner at postoperative days 1-7 and day 30, with documentation of complications involving:

Cardiovascular system; Respiratory system; Digestive system; Nervous system; Urinary system; Infection-related complications,such as wound infection Postoperative complications are defined as adverse events of Clavien Dindo grade II or higher occurring in any system from postoperative day 1 to day 7 (or the day of discharge) and within 30 days after surgery.

From the start of surgery to 30 days post-operation
Length of hospital stay
Aikaikkuna: From patient admission to discharge, assessed up to 2 weeks after surgery
the duration of patient stay in hospital
From patient admission to discharge, assessed up to 2 weeks after surgery
Rate of second operation
Aikaikkuna: From immediately after surgery to 30 days postoperatively
Observation and record the rate of secondary surgeries
From immediately after surgery to 30 days postoperatively
Mortality within 30-day postoperatively
Aikaikkuna: From immediately after surgery to 30 days postoperatively
Record the mortality within 30 days postoperatively.
From immediately after surgery to 30 days postoperatively
Incidence of acute myocardial injury
Aikaikkuna: From anesthesia induction to 24 hours after surgery
Measure blood cardiac troponin I level at the following time points: Preoperatively and 24 hours postoperatively, measurement of cardiac troponin I exceeds the 99th percentile upper reference limit
From anesthesia induction to 24 hours after surgery
Incidence of acute kidney injury
Aikaikkuna: From anesthesia induction to 24 hours after surgery

Measure blood creatinine level at the following time points:

1 day before surgery, and 24 hours postoperatively;Acute kidney injury was defined according to the KDIGO criteria as the presence of any of the following: (1) an increase in serum creatinine by ≥26.5 μmol/L (0.3 mg/dL) within 48 hours; (2) an increase in serum creatinine to ≥1.5 times baseline within the previous 7 days; or (3) a urine volume <0.5 mL/kg/h for 6 consecutive hours.

From anesthesia induction to 24 hours after surgery
Incidence of postoperative surgical site infection
Aikaikkuna: From immediately after surgery to 30 days postoperatively
surgical site infection refers to the proportion of surgical cases with surgical site infection (SSI) occurring from after surgery to before discharge, relative to the total number of surgical procedures performed on hospitalized patients during the same period. Postoperative wound infection is defined as an infection related to the surgical procedure and occurring near the surgical site within 30 days after surgery. Postoperative wound infections include: superficial incisional SSI, deep incisional SSI, and organ/space SSI.
From immediately after surgery to 30 days postoperatively
Heart rate change immediately after intubation
Aikaikkuna: at anesthesia induction and immediately after intubation, assessed up to 10 seconds after intubation
Record heart rate before induction and immediately after completion of intubation, and calculate the magnitude of change.
at anesthesia induction and immediately after intubation, assessed up to 10 seconds after intubation
Duration to postoperative first flatus time
Aikaikkuna: From the end of surgery to 7 days after surgery
Duration to postoperative first flatus time
From the end of surgery to 7 days after surgery
Duration to postoperative first oral intake
Aikaikkuna: From the end of surgery to 7 days after surgery
Duration to postoperative first oral intake
From the end of surgery to 7 days after surgery
Minimum intraoperative mean arterial pressure
Aikaikkuna: From the anesthesia induction to the end of surgery, assesed up to 5 minutes after surgery

Parameters to be recorded:

Minimum intraoperative mean arterial pressure ;

From the anesthesia induction to the end of surgery, assesed up to 5 minutes after surgery
Incidence of hypotension.
Aikaikkuna: From the anesthesia induction to the end of surgery, assesed up to 5 minutes after surgery

Parameters to be recorded:

Incidence of hypotension;

Hypotension is defined as:

Mean arterial pressure < 65 mmHg or decrease of mean arterial pressure > 20% from preoperative baseline value.

From the anesthesia induction to the end of surgery, assesed up to 5 minutes after surgery
Durations of post-anesthesia care unit stay
Aikaikkuna: From entering post-anesthesia care unit to post-anesthesia care unit discharge, assessed up to 2 hours after entering post-anesthsia care unit
Duration of post-anesthesia care unit stay
From entering post-anesthesia care unit to post-anesthesia care unit discharge, assessed up to 2 hours after entering post-anesthsia care unit
Cumulative postoperative oxycodone dosage
Aikaikkuna: From the initiation of patient controlled intravenous analgesia pump use to the discontinuation of analgesic pump use, assessed up to 3 days after surgery
Cumulative postoperative oxycodone dose
From the initiation of patient controlled intravenous analgesia pump use to the discontinuation of analgesic pump use, assessed up to 3 days after surgery
The duration of intraoperative deep sedation
Aikaikkuna: from anesthesia induction to the end of surgery, assessed up to 5 minutes after surgery
The duration of intraoperative wavelet index below 40 or Bispectral Index below 40
from anesthesia induction to the end of surgery, assessed up to 5 minutes after surgery
The duration of intraoperative inadequate analgesia
Aikaikkuna: from anesthesia induction to the end of surgery, assessed up to 5 minutes after surgery
The duration of intraoperative pain threshold index higher than 70
from anesthesia induction to the end of surgery, assessed up to 5 minutes after surgery
Scores of Intake, Feeling nauseated, Emesis, physical Exam, and Duration of symptoms at 72 hours after surgery
Aikaikkuna: at 72 hours after surgery
Scores of Intake, Feeling nauseated, Emesis, physical Exam, and Duration of symptoms at 72 hours after surgery, Intake, Feeling nauseated, Emesis, physical Exam, and Duration of symptoms is a scoring system to evaluate the postoperative gastrointestinal function, if the score is higher than 6, it indicating gastrointestinal dysfunction.
at 72 hours after surgery

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Tutkijat

  • Päätutkija: Tianlong Wang, Doctor, Xuanwu Hospital, Beijing

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Yleiset julkaisut

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Lauantai 1. elokuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Tiistai 30. toukokuuta 2028

Opintojen valmistuminen (Arvioitu)

Lauantai 30. joulukuuta 2028

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Maanantai 13. heinäkuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Keskiviikko 15. heinäkuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Maanantai 20. heinäkuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Maanantai 20. heinäkuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Keskiviikko 15. heinäkuuta 2026

Viimeksi vahvistettu

Keskiviikko 1. heinäkuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • Linyanshen[2025]075-004-xz-1

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-jaon aikakehys

One year after results publicated

IPD-jaon käyttöoikeuskriteerit

Contacting the corresponsible author.

IPD-jakamista tukeva tietotyyppi

  • STUDY_PROTOCOL

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa